Insmed Incorporated (NASDAQ:INSM) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET

Company Participants

Bryan Dunn – Head-Investor Relations
Will Lewis – Chair and Chief Executive Officer
Sara Bonstein – Chief Financial Officer
Martina Flammer – Chief Medical Officer

Conference Call Participants

Jessica Fye – JPMorgan
Ritu Baral – TD Cowen
Joseph Schwartz – Leerink Partners
Cameron Bozdog – Bank of America
Jennifer Kim – Cantor Fitzgerald
Leon Wang – Barclays
Vamil Divan – Guggenheim Securities
Liisa Bayko – Evercore ISI
Graig Suvannavejh – Mizuho
Nicole Germino – Truist Securities
Andrea Tan – Goldman Sachs

Operator

Thank you for standing by. My name is John, and I will be your conference operator for today. At this time, I would like to welcome everyone to the Insmed Second Quarter 2024 Financial Results Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions]

I would now like to turn the call over to Bryan Dunn, Head of Investor Relations. Please go ahead.

Bryan Dunn

Thank you, John. Good day, everyone, and welcome to today's conference call to discuss Insmed's second quarter 2024 financial results and provide a business update. I am joined today by Will Lewis, Chair and Chief Executive Officer; and Sara Bonstein, Chief Financial Officer, who will each provide prepared remarks, after which, they will be joined by Martina Flammer, Chief Medical Officer, for the Q&A session.

Before we start, please note that today's call will include forward-looking statements based on our current expectations. These statements represent our judgment as of today and inherently involve risks and uncertainties that may cause actual results to differ materially from the results discussed. Please refer to our filings with the Securities and Exchange Commission for more information concerning the risk factors that could affect the company. The information we will discuss on today's call is meant for the benefit of the investment community. It is not intended for promotional purposes and it is not sufficient for prescribing decisions.

I will now turn the call over to Will Lewis for prepared remarks.

Will Lewis

Thank you, Bryan, and welcome, everyone. The second quarter of 2024 will go down in Insmed's history as the start of an important new era as a mid-cap biotechnology company. During this quarter, we not only saw the continued growth of ARIKAYCE in refractory MAC lung disease, but also positive Phase 2 data for TPIP and PH-ILD, and of course, most significantly, the successful results of the landmark ASPEN study.